Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11365-11374

  Bao, Lei ^a   Liu, Feng ^b   Guo, Huai bin ^c   Li, Yong ^a   Tan, Bi bo ^a   Zhang, Wan xing ^c   Peng, Yan hui ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Third Hospital of Shijiazhuang City   (China)

^c HEBEI GENERAL HOSPITAL   (China)

Author keywords

Gastric cancer; Invasion; Naringenin; Proliferation; Signal transduction pathway

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLINE; GELATINASE A; GELATINASE B; NARINGENIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SURVIVIN; ANTINEOPLASTIC AGENT; FLAVANONE DERIVATIVE;

ANTIGEN EXPRESSION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GASTRIC CANCER CELL LINE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SGC7901 CELL LINE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FLAVANONES; HUMANS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84960088814     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5013-2     Document Type: Article

References (37)

1. Piazuelo MB, Correa P. Gastric cancer: overview. Colomb Med (Cali). 2013;44:192–201.
2. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380:1840–50.
3. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy—from TCM theory to mechanistic insights. Planta Med. 2010;76:1118–31.
4. Meiyanto E, Hermawan A, Anindyajati. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13:427–36.
5. Bodet C, La VD, Epifano F, Grenier D. Naringenin has anti-inflammatory properties in macrophage and ex vivo human whole-blood models. J Periodontal Res. 2008;43:400–7.
6. Lee CH, Jeong TS, Choi YK, Hyun BH, Oh GT, et al. Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun. 2001;284:681–8.
7. Wang J, Yang Z, Lin L, Zhao Z, Liu Z, et al. Protective effect of naringenin against lead-induced oxidative stress in rats. Biol Trace Elem Res. 2012;146:354–9.
8. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.
9. Maggioni D, Nicolini G, Rigolio R, Biffi L, Pignataro L, et al. Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro. Nutr Cancer. 2014;66:1257–67.
10. Li RF, Feng YQ, Chen JH, Ge LT, Xiao SY, et al. Naringenin suppresses K562 human leukemia cell proliferation and ameliorates adriamycin-induced oxidative damage in polymorphonuclear leukocytes. Exp Ther Med. 2015;9:697–706.
11. Liao AC, Kuo CC, Huang YC, Yeh CW, Hseu YC, et al. Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2. Mol Med Rep. 2014;10:1531–6.
12. Yen HR, Liu CJ, Yeh CC. Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015;235:1–9.
13. Qin L, Jin L, Lu L, Lu X, Zhang C, et al. Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell. 2011;2:507–16.
14. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev. 2012;31:323–51.
15. Mir IA, Tiku AB. Chemopreventive and therapeutic potential of “naringenin,” a flavanone present in citrus fruits. Nutr Cancer. 2015;67:27–42.
16. Krishnakumar N, Sulfikkarali NK, Manoharan S, Nirmal RM. Screening of chemopreventive effect of naringenin-loaded nanoparticles in DMBA-induced hamster buccal pouch carcinogenesis by FT-IR spectroscopy. Mol Cell Biochem. 2013;382:27–36.
17. Sulfikkarali N, Krishnakumar N, Manoharan S, Nirmal RM. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(A)anthracene induced experimental oral carcinogenesis. Pathol Oncol Res. 2013;19:287–96.
18. Shi WT, Wei L, Xiang J, Su K, Ding Q, et al. Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes. Asian Pac J Cancer Prev. 2012;13:5263–72.
19. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.
20. Pontier SM, Muller WJ. Integrins in breast cancer dormancy. APMIS. 2008;116:677–84.
21. Li H, Zhu F, Chen H, Cheng KW, Zykova T, et al. 6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1. Cancer Res. 2014;74:243–52.
22. Lee JH, Park CH, Jung KC, Rhee HS, Yang CH. Negative regulation of beta-catenin/Tcf signaling by naringenin in AGS gastric cancer cell. Biochem Biophys Res Commun. 2005;335:771–6.
23. Ekambaram G, Rajendran P, Magesh V, Sakthisekaran D. Naringenin reduces tumor size and weight lost in N-methyl-N′-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Nutr Res. 2008;28:106–12.
24. Ekambaram G, Rajendran P, Devaraja R, Muthuvel R, Sakthisekaran D. Impact of naringenin on glycoprotein levels in N-methyl-N′-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Anti Cancer Drugs. 2008;19:885–90.
25. Yang L, Allred KF, Geera B, Allred CD, Awika JM. Sorghum phenolics demonstrate estrogenic action and induce apoptosis in nonmalignant colonocytes. Nutr Cancer. 2012;64:419–27.
26. Bulzomi P, Bolli A, Galluzzo P, Acconcia F, Ascenzi P, et al. The naringenin-induced proapoptotic effect in breast cancer cell lines holds out against a high bisphenol a background. IUBMB Life. 2012;64:690–6.
27. Matsuzawa A, Nishitoh H, Tobiume K, Takeda K, Ichijo H. Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signal. 2002;4:415–25.
28. Rooswinkel RW, van de Kooij B, de Vries E, Paauwe M, Braster R, et al. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood. 2014;123:2806–15.
29. Kotsafti A, Farinati F, Cardin R, Cillo U, Nitti D, et al. Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. BMC Gastroenterol. 2012;12:118.
30. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev. 2005;15:87–96.
31. Singh D, Srivastava SK, Chaudhuri TK, Upadhyay G. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci. 2015;2:19.
32. Fields GB. New strategies for targeting matrix metalloproteinases. Matrix Biol. 2015;44–46:239–46.
33. Sampieri CL, de la Peña S, Ochoa-Lara M, Zenteno-Cuevas R, León-Córdoba K. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World J Gastroenterol. 2010;16:1500–5.
34. Chtourou Y, Fetoui H, Jemai R, Ben Slima A, Makni M, et al. Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor κB pathway. Eur J Pharmacol. 2015;746:96–105.
35. Qin Y, Ye GX, Wu CJ, Wang S, Pan DB, et al. Effect of DAPK1 gene on proliferation, migration, and invasion of carcinoma of pancreas BxPC-3 cell line. Int J Clin Exp Pathol. 2014;7:7536–44.
36. Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM, et al. Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma. Mol Carcinog. 2014;53:635–47.
37. Wen W, Wu J, Liu L, Tian Y, Buettner R, et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 2015;14:100.